History
  • No items yet
midpage
In Re Diet Drugs (Phentermine/Fenfluramine/Dexfenfluramine) Product Liability Litigation
706 F.3d 217
3rd Cir.
2013
Read the full case

Background

  • Wyeth settled with diet drug users in a nationwide class action; PTO retained exclusive jurisdiction to administer the settlement.
  • Settlement includes an exception allowing claims for PPH if the plaintiff proves absence of greater than mild restrictive lung disease via pulmonary function tests (PFTs) showing total lung capacity >60% of predicted at rest.
  • Cauthens filed a state court suit claiming PPH from diet drugs; Wyeth moved to enjoin based on the Settlement Agreement.
  • Dr. Fortin submitted a declaration stating Ms. Cauthen’s TLC was 56% and argued reference values are uncertain, suggesting possible PPH causation by diet drugs.
  • District Court enjoined the state suit; the appeal challenges the interpretation of the PPH exception and the potential reformation of the Settlement Agreement.

Issues

Issue Plaintiff's Argument Defendant's Argument Held
Whether Fortin’s declaration can substitute for a PFT to satisfy § I.46.a(2)(c). Cauthens contend declaration confirms PPH causation. Wyeth argues only a PFT showing >60% is sufficient under the Agreement. Declaration cannot replace a PFT; settlement unambiguously requires >60% PFT.
Whether the Settlement Agreement should be reformed due to changes in diagnostic procedures. Cauthens urge reformation because modern diagnostics differ. Wyeth argues the issue was not properly raised below and waiver applies. Waived issue; no exceptional circumstances to reform the agreement.

Key Cases Cited

  • Glenn Distribs. Corp. v. Carlisle Plastics, Inc., 297 F.3d 294 (3d Cir. 2002) (contract interpretation from four corners; ambiguous contract standard)
  • In re Cendant Corp. Prides Litig., 233 F.3d 188 (3d Cir. 2000) (plenary review of settlement agreements; contract law governing interpretation)
  • Paoli R.R. Yard PCB Litig. v. Union Carbide, 35 F.3d 717 (3d Cir. 1994) (Daubert/Rule 702 standards for expert testimony applied to admissibility)
  • Tri-M Grp., L.L.C. v. Sharp, 638 F.3d 406 (3d Cir. 2011) (waiver rule for new arguments on appeal)
  • Rufo v. Inmates of Suffolk Cnty. Jail, 502 U.S. 367 (1992) (change in factual or legal conditions may justify modification of settlement)
Read the full case

Case Details

Case Name: In Re Diet Drugs (Phentermine/Fenfluramine/Dexfenfluramine) Product Liability Litigation
Court Name: Court of Appeals for the Third Circuit
Date Published: Jan 28, 2013
Citation: 706 F.3d 217
Docket Number: 12-1180
Court Abbreviation: 3rd Cir.